UPDATE: MLV & Co Reiterates On Galectin Therapeutics Following Cohort 2 Results
July 30, 2014 at 07:41 AM EDT
In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galectin Therapeutics (NASDAQ: GALT), ...